Kala Pharma reports $52.4M cash; plans Phase 2/3 trial for KPI-012 in Q4 2022 with data 1Q 2024

KALA BIO, Inc.

Cash and equivalents of $52.4M as of Sept 30, 2022, expected to fund operations into Q2 2024.
Plans to initiate Phase 2/3 trial of KPI-012 for PCED in Q4 2022; topline data expected Q1 2024.
Appointed Marjan Farid, M.D., to Board of Directors in November 2022.
Effected 1-for-50 reverse stock split on October 20, 2022.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

KALA BIO, Inc. reported financial results for the third quarter ended September 30, 2022.

Period: the third quarter ended September 30, 2022
Result: reported results

Exact text from the filing

On November 8, 2022, Kala Pharmaceuticals, Inc. announced its financial results for the quarter ended September 30, 2022

View on SEC.gov

39 earnings releases filed in the last 30 days. Browse all earnings releases →

KALA BIO, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-22-016752

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.